Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Johnson & Johnson
(NY:
JNJ
)
160.13
+0.27 (+0.17%)
Official Closing Price
Updated: 7:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
5,256,655
Open
160.58
Bid (Size)
160.01 (5)
Ask (Size)
161.50 (1)
Prev. Close
159.86
Today's Range
159.88 - 161.06
52wk Range
143.13 - 168.85
Shares Outstanding
2,628,679,824
Dividend Yield
2.97%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
October 28, 2024
Global psychedelic drugs market to reach $10.2 billion by 2028, driven by mental health needs and evolving regulatory support.
Via
Benzinga
Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease
October 28, 2024
Johnson & Johnson's Tremfya shows promising results in Phase 3 GRAVITI study for Crohn's disease, achieving significant clinical remission and endoscopic response at 48 weeks.
Via
Benzinga
Performance
YTD
+0.10%
+0.10%
1 Month
-0.23%
-0.23%
3 Month
-0.69%
-0.69%
6 Month
+7.77%
+7.77%
1 Year
+5.81%
+5.81%
More News
Read More
3 Dividend Growth Stocks You Can Buy and Hold Forever
October 26, 2024
Via
The Motley Fool
Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas
October 25, 2024
Via
Benzinga
Comparative Study: Johnson & Johnson And Industry Competitors In Pharmaceuticals Industry
October 24, 2024
Via
Benzinga
Peering Into Johnson & Johnson's Recent Short Interest
October 22, 2024
Via
Benzinga
Johnson & Johnson Unusual Options Activity
October 18, 2024
Via
Benzinga
Meet the Only 2 Game-Changing Businesses With a Higher Credit Rating Than the U.S. Government
October 24, 2024
Via
The Motley Fool
3 Simple Vanguard ETFs to Buy With $1,000 and Hold for a Lifetime
October 23, 2024
Via
The Motley Fool
Topics
ETFs
This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
October 23, 2024
Via
The Motley Fool
Justice Department's Trustee Program Alleges Johnson & Johnson's Talc Litigation Bankruptcy Bid Is Bad-Faith Tactic To Avoid Liability
October 22, 2024
Via
Benzinga
Topics
Bankruptcy
Lawsuit
Exposures
Financial
Legal
Starboard Hammers Pfizer Execs For Failing To Deliver On 'Best Pipeline' Promises
October 22, 2024
Via
Investor's Business Daily
What's Going On With Kenvue Stock Monday?
October 21, 2024
Via
Benzinga
Starboard Value Buys Into Dow Jones Spinoff; Elf Beauty Rallies
October 21, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Activist Investor Starboard Acquires Stake In Band-Aid Maker Kenvue, Shares Jump
October 21, 2024
Via
Talk Markets
Tylenol, Listerine Maker Kenvue Under Activist Spotlight With Starboard Value Stake — Overhaul Ahead For The Johnson & Johnson Spinoff?
October 20, 2024
Via
Benzinga
All It Takes Is $2,500 Invested in Each of These 3 High-Yield Dow Dividend Stocks to Help Generate Over $300 in Passive Income Per Year
October 19, 2024
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
October 19, 2024
Via
The Motley Fool
Three Safe Dividend Kings to Weather Any Storm
October 18, 2024
Via
Talk Markets
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
October 18, 2024
Via
Benzinga
Stock Market Rally At Highs; Taiwan Semi, ASML, Netflix In Focus: Weekly Review
October 18, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
3 No-Brainer Pharmaceutical Stocks to Buy With $500 Right Now
October 18, 2024
Via
The Motley Fool
This Magnificent Dividend Stock Is as Healthy as It Gets
October 17, 2024
Via
The Motley Fool
Johnson & Johnson's MedTech Challenges Loom Amid Chinese Market Pressures And Orthopedics Overhaul, Analysts Say
October 16, 2024
Via
Benzinga
Johnson & Johnson Stock: Setting the Stage for 2025 Highs
October 16, 2024
Via
MarketBeat
Exposures
COVID-19
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.